Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 10;12:5781–5795. doi: 10.2147/IJN.S140179

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Shi et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

The role of different endocytic pathways in the uptake of HAPs in HUVECs.

Notes: Cells were exposed to HAPs either with or without cpz, mβcd and cytoD. (A) CLSM images of HAP interactions with HUVECs for 2 h. Cells stained for nuclei (blue) and actin (red). HAPs are shown in green. Scale bar: 50 μm. (B) Quantification of the uptake of HAPs after HUVECs were treated with HAPs for 2 h. ^*P<0.01 versus no inhibitor control, ^&P<0.01 versus m-HAP group, ^#P<0.01 versus np20 group.

Abbreviations: CLSM, confocal laser scanning microscopy; cpz, chlorpromazine; cytoD, cytochalasin D; HAP, hydroxyapatite; HUVECs, human umbilical vein endothelial cells; mβcd, methyl-β-cyclodextrin; m-HAP, micro-sized HAP particles.